These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
487 related articles for article (PubMed ID: 36146723)
21. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine. Vu DM; Vu DTB; Do TTT; Olmsted AE; Dao BH; Thai TT; Nguyen CL; Le NTT; Le TA; Bui HTT; Pham TN; Moore MR Clin Infect Dis; 2022 Oct; 75(Suppl 2):S174-S181. PubMed ID: 35723271 [TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. Song YC; Liu SJ; Lee HJ; Liao HC; Liu CT; Wu MY; Yen HR J Microbiol Immunol Infect; 2023 Aug; 56(4):705-717. PubMed ID: 37055256 [TBL] [Abstract][Full Text] [Related]
23. Single ChAdOx1 nCoV-19 dose elicits stronger immune response in previously infected individuals than in SARS-CoV2 naive persons. Ebrahim F; Alboueishi A; Alhudiri IM; Tabal SA; Lamami Y; Al Dwigen S; Ashleb S; Ejenfawi N; Milad MB; Rhoumah H; El Meshri SE; Elzagheid A Immun Inflamm Dis; 2024 Jan; 12(1):e1159. PubMed ID: 38270312 [TBL] [Abstract][Full Text] [Related]
24. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E Front Immunol; 2022; 13():981350. PubMed ID: 36059485 [TBL] [Abstract][Full Text] [Related]
25. Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2- seropositive individuals. Fernandes ER; Taminato M; de Souza Apostolico J; Gabrielonni MC; Lunardelli VAS; Maricato JT; Andersen ML; Tufik S; Rosa DS J Allergy Clin Immunol Glob; 2023 May; 2(2):100083. PubMed ID: 36845213 [TBL] [Abstract][Full Text] [Related]
26. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization. Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations. Lee TH; Nam M; Seo JD; Kim H; Kim HR; Hur M; Yun YM; Moon HW Ann Lab Med; 2023 May; 43(3):290-294. PubMed ID: 36544341 [TBL] [Abstract][Full Text] [Related]
28. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days. Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R Front Immunol; 2021; 12():726960. PubMed ID: 34671348 [TBL] [Abstract][Full Text] [Related]
29. Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis. Yu ZY; Lai CF; Lai TS; Yang SY; Chen SI; Lai MJ; Kang CM; Huang YT; Chen YT; Hsueh PR; Chen YM; Lin SL J Formos Med Assoc; 2023 Sep; 122(9):922-931. PubMed ID: 36894486 [TBL] [Abstract][Full Text] [Related]
30. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
31. Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. Mangia A; Serra N; Cocomazzi G; Giambra V; Antinucci S; Maiorana A; Giuliani F; Montomoli E; Cantaloni P; Manenti A; Piazzolla V Front Public Health; 2022; 10():847384. PubMed ID: 35433614 [TBL] [Abstract][Full Text] [Related]
32. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age. Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809 [TBL] [Abstract][Full Text] [Related]
33. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy. Polvere I; Parrella A; Zerillo L; Voccola S; Cardinale G; D'Andrea S; Madera JR; Stilo R; Vito P; Zotti T Front Immunol; 2022; 13():833085. PubMed ID: 35634315 [TBL] [Abstract][Full Text] [Related]
34. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Smith M; Kwatra G; Izu A; Nel A; Cutland C; Ahmed K; Baillie V; Barnabas S; Bhorat Q; Briner C; Lazarus E; Dheda K; Fairlie L; Koen A; Madhi S; Blackburn JM Viruses; 2023 Feb; 15(2):. PubMed ID: 36851662 [TBL] [Abstract][Full Text] [Related]
36. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort. Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of T and B cell immunophenotyping and antibody response post Covid-19 vaccination. Chadha R; Ds U; Phogat R; Alam S; Mathur N; Singh M; Kataria S; Sharma P; Singh P; Sarma S; Saxena R; Ganguly NK; Trehan N Indian J Med Microbiol; 2023; 44():100372. PubMed ID: 37356831 [TBL] [Abstract][Full Text] [Related]
38. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency. Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I Front Immunol; 2022; 13():907125. PubMed ID: 35784359 [TBL] [Abstract][Full Text] [Related]
39. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895 [TBL] [Abstract][Full Text] [Related]
40. Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers. Smit W; Thijsen S; van der Kieft R; van Tol S; Reimerink J; Reusken C; Rümke L; Bossink A; Limonard G; Heron M Pathog Dis; 2022 Oct; 80(1):. PubMed ID: 36089571 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]